Read Time:1 Minute, 53 Second
The total amount of the contract is $360 million, which corresponds to 63% of the total revenue of Samsung Biologics in 2019. Samsung Biologics will start producing drugs for treating coronavirus infection COVID-19 right after Vir Biotechnology completes its development. Earlier, the leading pharmaceutical company GlaxoSmithKline announced a decision to invest up to $250 million in Vir Biotechnology to finance two long-term projects to develop a vaccine to prevent viral infection. Right now, Vir Biotechnology researchers are creating a potential vaccine. At the moment, the drug is called “SARS-CoV-2 monoclonal antibodies,” and, as the name implies, it is based on monoclonal antibodies.
According to officials and experts, antibody-based drugs can be used in three possible ways:
- To prevent infection of people at high risk, such as health workers.
- To prevent the development of serious respiratory diseases that may develop due to COVID-19 infection.
- For the treatment of patients with severe respiratory diseases caused by COVID-19.
Join Our WhatsApp Group For More Quick & Easy Updates: Group 1: Click Here! Group 2: Click Here! Group 2: Click Here!